Low molecular weight heparins in the treatment of lung cancer

被引：11

作者：

Mellema, Wouter W. ^{[4
]}

Smit, Egbert F. ^{[4
]}

Dingemans, Anne-Marie C. ^{[1
,2
,3
]}

机构：

[1] Maastricht Univ Med Ctr, Dept Pulmonol, NL-6202 AZ Maastricht, Netherlands

[2] Maastricht Univ Med Ctr, GROW Sch Oncol, NL-6202 AZ Maastricht, Netherlands

[3] Maastricht Univ Med Ctr, Dev Biol, NL-6202 AZ Maastricht, Netherlands

[4] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 11期

关键词：

low molecular weight heparin; lung cancer; thromboembolic events; RECURRENT VENOUS THROMBOEMBOLISM; DEEP-VEIN THROMBOSIS; RANDOMIZED PHASE-III; CLINICAL-TRIAL; ADVANCED MALIGNANCY; SURVIVAL; RISK; CHEMOTHERAPY; GEMCITABINE; COMBINATION;

D O I：

10.1517/13543784.2011.625008

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Introduction: Lung cancer is the major cause of cancer-related death. Venous thromboembolic events (VTEs) occur frequently in lung cancer and are a poor prognostic marker. For prevention and treatment of VTE, low molecular weight heparins (LMWH) are superior to vitamin K antagonists. There is some evidence that LMWH may improve survival in cancer patients. Areas covered: The areas covered in this review are: lung cancer and VTEs; role of LMWH in treatment of VTEs; anticancer mechanism of heparins and clinical trials with LMWH in lung cancer. Expert opinion: LMWH plays an important role in prevention and treatment of VTEs in lung cancer. Although there is evidence from both preclinical data and retrospective analysis of clinical trials that LMWH may prolong survival this is not confirmed by prospective randomized clinical trials. Several clinical trials on this subject in lung cancer are ongoing and have to be awaited.

引用

页码：1517 / 1522

页数：6

共 44 条

[1]

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study [J].

Agnelli, Giancarlo ;

Gussoni, Gualberto ;

Bianchini, Carlo ;

Verso, Melina ;

Mandala, Mario ;

Cavanna, Luigi ;

Barni, Sandra ;

Labianca, Roberto ;

Buzzi, Franco ;

Scambia, Giovanni ;

Passalacqua, Rodolfo ;

Ricci, Sergio ;

Gasparini, Giampietro ;

Lorusso, Vito ;

Bonizzoni, Erminio ;

Tonato, Maurizio .

LANCET ONCOLOGY, 2009, 10 (10) :943-949

[2]

Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review [J].

Akl, Elie A. ;

Barba, Maddalena ;

Rohilla, Sandeep ;

Terrenato, Irene ;

Sperati, Francesca ;

Muti, Paola ;

Schuenemann, Holger J. .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2008, 27 (1)

[3]

ALBERT-WEIL J, 1954, Rev Pathol Gen Physiol Clin, V54, P1014

[4]

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer [J].

Altinbas, M ;

Coskun, HS ;

Er, O ;

Ozkan, M ;

Eser, B ;

Unal, A ;

Cetin, M ;

Soyuer, S .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (08) :1266-1271

[5]

Incidence of venous thrombosis in a large cohort of 66 329 cancer patients:: results of a record linkage study [J].

Blom, JW ;

Vanderschoot, JPM ;

Oostindiër, MJ ;

Osanto, S ;

van der Meer, FJM ;

Rosendaal, FR .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (03) :529-535

[6]

Malignancies, prothrombotic mutations, and the risk of venous thrombosis [J].

Blom, JW ;

Doggen, CJM ;

Osanto, S ;

Rosendaal, FR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (06) :715-722

[7]

Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis [J].

Borsig, L ;

Wong, R ;

Feramisco, J ;

Nadeau, DR ;

Varki, NM ;

Varki, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) :3352-3357

[8]

The heparins and cancer: review of clinical trials and biological properties [J].

Castelli, R ;

Porro, F ;

Tarsia, P .

VASCULAR MEDICINE, 2004, 9 (03) :205-213

[9]

Dingemans AC, 2008, ANN ONCOL, V19, P97

[10]

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism -: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency [J].

Dolovich, LR ;

Ginsberg, JS ;

Douketis, JD ;

Holbrook, AM ;

Cheah, G .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (02) :181-188

← 1 2 3 4 5 →